SeaStar Medical Holding Corporation
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
The complaint claims that the Company and its executives broke federal securities laws by making false or misleading statements and failing to disclose the following: (i) SeaStar and/or Legacy SeaStar had inadequate compliance controls and procedures for the HDE Application; (ii) as a result, there were problems with the HDE Application, the FDA was unlikely to approve it as it was, and the SCD’s regulatory prospects were exaggerated; (iii) the Company downplayed the real extent of issues with its financial controls and procedures while overstating efforts to fix them; (iv) consequently, SeaStar failed to correctly account for certain outstanding warrants and the Prepaid Forward Agreement; (v) as a result, SeaStar might need to restate one or more of its past financial statements; (vi) therefore, SeaStar’s business and financial prospects after the Merger were exaggerated; and (vii) this made the Company’s public statements misleading at all relevant times.
On March 27, 2024, SeaStar announced it will restate its financial statements for the fiscal year ending December 31, 2022, and for interim periods ending March 31, 2023, June 30, 2023, and September 30, 2023. The Company said the restatement will affect how certain outstanding warrants and the prepaid forward purchase arrangement, terminated in June 2023, are accounted for. SeaStar’s CEO explained that the restatement would not significantly affect the Company’s operations or cash position, but was related to non-cash accounting items. The CEO also noted that the decision to use a Special Purpose Acquisition Company (SPAC) to go public in late 2022, due to challenging market conditions, involved complex financial instruments. It was later determined that these instruments required different accounting treatment than previously judged, leading to the need for a restatement.
Following this announcement, SeaStar’s stock price dropped by $0.04 per share, or 5.41%, closing at $0.70 per share on March 27, 2024.
